Making the world's nanotechnology knowledge accessible at your fingertips, driven by our novel AI algorithm.

Unleashing the power of nanotechnology

Leverage experimental data to accelerate the R&D of your nanoformulations.

49/50
cancer drugsfailFDA - approvalAn icon representing a medical fluid bag.
up to150
new therapeutics/yearpotentiallycan be commercializedAn icon representing a pill.
Sun DX et al. Acta Pharmaceutica Sinica B. 2022; Fawcett N. University of Michigan. Michigan Medicine. 2016.

nanoML is our revolutionary pre-clinical R&D platform that harnesses the combined knowledge of the nanotechnology, biology, and AI.

A Venn Diagram showing therapeutic delivery biology, nanoparticle science, and computational biophysics overlapping.

We empower scientists across therapeutic areas to personalize therapeutic formulations at any R&D stage.

A laptop with nanoML showing on the screen.

The nanoML analytics platform extracts, indexes, and displays the formulation and experimental data from peer-reviewed publications.

A laptop with nanoML showing on the screen.

Scientists can design, screen, and compare the performance of their therapeutic formulations to accelerate pre-clinical R&D.

Enhance the R&D speed and increase the yield of your portfolio exponentially, not incrementally.

A chart depicting the usual drug development timeline, from discovery to regulatory approval.

Matthews H et al. Proteomes. 2016.